Autopsy report · NCT06214403
Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation
Cause of deathDrug or device supply
“Study intervention not available. Manufacturer no longer producing MET-2.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Conditions
- Gram-negative Bacteremia; Microbial Colonization; Antibiotic Resistant Infection
- Interventions
- MET-2; Placebo
- Participants
- 0
- Sites
- 4
- Countries
- Canada
Trials that died the same way
- Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
“Study discontinued due to low accrual.” - Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
“Study discontinued due to futility.” - Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
“Study was terminated early due to lack of experimental medication (supply issues)” - A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
“Study stopped due to lack of efficacy \& funding.” - KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
“Study discontinued due to sponsor decision.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.